CorMedix Inc. · NASDAQ:CRMD

CorMedix — Merger or Acquisition (November 2026)

7 slides from CorMedix's merger presentation, Nov 10, 2026

  1. Slide 1: Acquisition of Heron Therapeutics Commercial and Pipeline Assets

    Slide 1: Acquisition of Heron Therapeutics Commercial and Pipeline Assets

    Acquisition of Heron Therapeutics Commercial and Pipeline Assets November 9, 2026 1

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Forward - Looking Statements: This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements are often iden

  3. Slide 3: Transaction Overview and Timeline

    Slide 3: Transaction Overview and Timeline

    Transaction Overview and Timeline 3 » Up to $55mm total earn - out payments based on ZYNRELEF ® net sales milestones: $25mm if ZYNRELEF ® net sales exceed $65mm for calendar year 2028, plus an additional $30mm if ZYNRELEF ® net sales exceed $95mm for calendar year 2028 Earn - out Payments » $145 mil

  4. Slide 4: Combined CorMedix and Heron Assets

    Slide 4: Combined CorMedix and Heron Assets

    Combined CorMedix and Heron Assets 4 1. Extends CorMedix’s portfolio into perioperative pain and CINV/PONV, addressing similar call points of hospitals, IDN, and ASC customers covered by the existing field organization 2. Complementary hematology/oncology commercial infrastructure that can be levera

  5. Slide 5: Highlights of Heron Commercial and Pipeline Assets

    Slide 5: Highlights of Heron Commercial and Pipeline Assets

    Highlights of Heron Commercial and Pipeline Assets 5 Established integrated acute care and hematology/oncology supportive care portfolio of four FDA - approved commercial brands, supported by a dedicated hospital and ambulatory surgery center (ASC) sales force with a broad footprint 1 Diversified Q3

  6. Slide 6: Summary of Heron's Commercial Portfolio

    Slide 6: Summary of Heron's Commercial Portfolio

    Acute Care Products Hematology/Oncology Care Products Dual - acting, extended - release anesthetic that combines local pain relief with anti - inflammatory effects Ready - to - use IV NK1 receptor antagonist offering rapid onset and sustained protection Extended - release 5 - HT3 receptor antagonist

  7. Slide 7: Combined Product Portfolio

    Slide 7: Combined Product Portfolio

    Combined Product Portfolio Creates a diversified portfolio with 12 commercial products and multiple near - term pipeline opportunities Commercial Ph III / Registrational Ph II Ph I Pre - Clinical Indication Product Hemodialysis CorMedix Total Parenteral Nutrition (TPN) Hemodialysis (Pediatric label

Source: SEC EDGAR · DEFA14A filed Nov 10, 2026

More decks from CorMedix Inc.

All 34 CorMedix decks